|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colchicine reduces procollagen Ⅲ and increases pseudocholinesterase in chronic liver disease显示文摘AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis. | Sergio Muntoni Marcos Rojkind Sandro Muntoni | 2010 | World Journal of Gastroenterology2010，16，23： | 14 |
| 2 | Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model显示文摘AIM To improve anti-inflammatory activity while reducing drug doses, we developed a nanoformulation carrying dexamethasone and butyrate.METHODS Dexamethasone cholesteryl butyrate-solid lipid nanoparticles(Dx Cb-SLN) were obtained with the warm microemulsion method. The anti-inflammatory activity of this novel nanoformulation has been investigated in vitro(cell adhesion to human vascular endothelial cells and pro-inflammatory cytokine release by lipopolysaccharideinduced polymorphonuclear cells) and in vivo(disease activity index and cytokine plasma concentrations in a dextran sulfate sodium-induced mouse colitis) models. Each drug was also administered separately to compare its effects with those induced by their co-administration in SLN at the same concentrations.RESULTS Dx Cb-SLN at the lowest concentration tested(Dx 2.5 nmol/L and Cb 0.1 μmol/L) were able to exert a more than additive effect compared to the sum of the individual effects of each drug, inducing a significant in vitro inhibition of cell adhesion and a significant decrease of pro-inflammatory cytokine(IL-1β and TNF-α) in both in vitro and in vivo models. Notably, only the Dx Cb nanoformulation administration was able to achieve a significant cytokine decrease compared to the cytokine plasma concentration of the untreated mice with dextran sulfate sodium-induced colitis. Specifically, Dx Cb-SLN induced a IL-1β plasma concentration of 61.77% ± 3.19%, whereas Dx or Cb used separately induced a concentration of 90.0% ± 2.8% and 91.40% ± 7.5%, respectively; Dx Cb-SLN induced a TNF-α plasma concentration of 30.8% ± 8.9%, whereas Dx or Cb used separately induced ones of 99.5% ± 4.9% and 71.1% ± 10.9%, respectively.CONCLUSION Our results indicate that the co-administration of dexamethasone and butyrate by nanoparticles may be beneficial for inflammatory bowel disease treatment. | Chiara Dianzani Federica Foglietta Benedetta Ferrara Arianna Carolina Rosa Elisabetta Muntoni Paolo Gasco Carlo Della Pepa Roberto Canaparo Loredana Serpe | 2017 | World Journal of Gastroenterology2017，23，23： | 3 |
| 3 | The in vitro and in vivo enantioselectivity of etomidate implicates the GABAA receptor in general anaesthesia显示文摘 | Muntoni AL Merrywest SD | 2003 | Neuropharmacology2003，45，1： | 1 |
| 4 | DNA damage induces alternative lengthening of telomeres (ALT) -asso-ciated promyelocytic Leukemia bodies that preferentially associate with linear telomeric DNA显示文摘 | Fasching CL Neumann AA Muntoni A | 2007 | Cancer Res2007，67，15： | 1 |
| 5 | 168th ENMC International Workshop: Outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT) 显示文摘 | REILLY MM SHY ME MUNTONI F | 2010 | Neuromuscul Disord2010，20，12： | 1 |
| 6 | Are human and mouse satellite cells really the same显示文摘 | BOLDRIN L MUNTONI F MORGAN J E | | 0，，11： | 1 |
| 7 | Localisation of merosin-positive congenital muscular dystrophy to chromosome 4p16.3显示文摘 | G. S. Sellick C. Longman M. Brockington I. Mahjneh L. Sagi K. Bushby H. Topalo?lu F. Muntoni R. S. Houlston | 2005 | Human Genetics (-)2005，，2： | 1 |
| 8 | Wolman disease due to homozygosity for a novel truncated variant of lysosomal acid lipase(351 insA)associated with complete in situ acid lipase deficiency显示文摘 | Seedorf U Muntoni S Mayatepek E | | 0，，1： | 1 |
| 9 | Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy显示文摘 | Simonds AK Muntoni F Heather S | 1998 | Thorax1998，53，： | 1 |
| 10 | Congenital muscle disorders with cores:The ryanodine receptor calcium channel paradigm 显示文摘 | TREVES S JUNGBLUTH H MUNTONI F | 2008 | Curr Opin Pharmacol2008，8，3： | 1 |
| 11 | Muscular dystrophies显示文摘 | Mercuri E1 Muntoni F | 2013 | Lancet2013，381，9869： | 1 |
| 12 | Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilat- ed cardiomyopathy 显示文摘 | Muntoni F Melis MA Ganan A | 1995 | Am J Hum Genet1995，56，： | 1 |
| 13 | Dystrophin and mutations: one genc, several proteins, multiple phenotypes 显示文摘 | Muntoni F Torclli S Ferlini A | 2003 | Lancet Neurol2003，2，： | 1 |
| 14 | Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families显示文摘 | Melis MA Can M Muntoni F | 1998 | Eur J Paediatr Neurol1998，2，： | 1 |
| 15 | Dystrophin and mutations: one gene, several proteins, multiple phenotypes 显示文摘 | Muntoni F Torelli S Ferlini A | 2003 | Lancet Neurol2003，，12： | 1 |
| 16 | Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement显示文摘 | Bordsky GL Muntoni F Miocic S | | 0，，： | 1 |
| 17 | Combined use of a transformed red mud reactive barrier and eleetrokineties for remediation of Cr/As contaminated soil 显示文摘 | CAPPAI G GIOANNIS G D MUNTONI A | 2012 | Chemosphere2012，86，： | 1 |
| 18 | Diagnosis and new treatments in muscular dystrophies 显示文摘 | Manzur AY Muntoni F | 2009 | J Neurol Neurosurg Psychiatry2009，80，7： | 1 |
| 19 | A point mutation in the 5-prime splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy显示文摘 | Milasin J muntoni F Severini G | | 0，，： | 1 |
| 20 | The first molecular details of ALT in human tumor cells显示文摘 | MUNTONI A REDDEL R R | 2005 | Hum Mol Genet2005，14，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员